Functional Improvement of Progenitor Cells and Endothelial Function by Vildagliptin in Diabetes Mellitus (FINNjA-DM). (FINNjA-DM)
Primary Purpose
SDF-1 is an Important Cytokine for Neovascularization. Cleavage of SDF-1 is Reduced by DPPIV Inhibitors
Status
Withdrawn
Phase
Phase 2
Locations
Germany
Study Type
Interventional
Intervention
Vildagliptin
Sponsored by
About this trial
This is an interventional basic science trial for SDF-1 is an Important Cytokine for Neovascularization. Cleavage of SDF-1 is Reduced by DPPIV Inhibitors focused on measuring CAD, diabetes, SDF-1, endothelial function
Eligibility Criteria
Inclusion Criteria:
- Patients with diabetes mellitus type 2 under stable medication
- HbA1c between 7% an 10%
- age between 18 and 80 years
- signed informed consent
Exclusion Criteria:
- Atrial fibrillation (plethysmographic recordings can only obtained in sinus-rhythm)
- CAD with reduced left ventricular ejection fraction (LVEF <45%)
- Pregnancy, chronic or acute infection, fever
- Diabetes mellitus type 1
- Newly diagnosed diabetes, uncontrolled diabetes
- Neoplasm
- Known allergy to study drug
- Severe liver/kidney disease
- HIV, Hepatitis
- Participation at other studies within the last 30 days
Sites / Locations
- Department of Cardiology
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Vildagliptin
Placebo
Arm Description
starting with vildagliptin for 30 days followed by placebo for 30 days
starting with placebo for 30 days followed by vildagliptin for 30 days
Outcomes
Primary Outcome Measures
Endothelial Function
Secondary Outcome Measures
Number and Function of Progenitor Cells
Full Information
NCT ID
NCT00936234
First Posted
July 8, 2009
Last Updated
August 31, 2020
Sponsor
Johann Wolfgang Goethe University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT00936234
Brief Title
Functional Improvement of Progenitor Cells and Endothelial Function by Vildagliptin in Diabetes Mellitus (FINNjA-DM).
Acronym
FINNjA-DM
Official Title
Functional Improvement of Progenitor Cells and Endothelial Function by Vildagliptin in Diabetes Mellitus (FINNjA-DM).
Study Type
Interventional
2. Study Status
Record Verification Date
August 2020
Overall Recruitment Status
Withdrawn
Why Stopped
insufficient recruitment
Study Start Date
July 2009 (undefined)
Primary Completion Date
September 2011 (Actual)
Study Completion Date
May 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Johann Wolfgang Goethe University Hospital
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
SDF-1, an important cytokine for neovascularisation is cleaved by (dipeptidyl peptidase IV) DPPIV.
The aim of this study is to assess the effect of the dipeptidyl peptidase IV inhibitor vildagliptin (Galvus®) on endothelial function as well as number and functional activity of progenitor cells in patients with documented diabetes mellitus.
Detailed Description
The peptidase CD26 (DPPIV/dipeptidyl peptidase IV) removes dipeptides from the amino terminus of proteins and thereby inactivates these cleaved proteins. It was shown, that CD26 cleaves SDF-1 into a non-mitogenic molecule. Inhibition or deletion of CD26 leads to an increased homing of hematopoietic progenitor cells to the bone marrow after transplantation by increasing the invasion capacity of these cells {Campbell et al. 2008; Christopherson et al. 2004}.
The cytokine SDF-1 is released in response to hypoxia, is crucial for progenitor cell homing and recruitment of cells for neovascularisation. Invasion capacity is closely related to the cytokine SDF-1 and the SDF-1 receptor CXCR4 {Ceradini et al. 2004}. The in vivo neovascularisation capacity of progenitor cells is closely correlated to their functional capacity as SDF-1 induced invasion or colony-forming capacity {Heeschen et al. 2004; Britten et al. 2003; Assmus et al. 2007}.
Therefore, the aim of this study is to assess the effect of the dipeptidyl peptidase IV inhibitor vildagliptin on endothelial function as well as number and functional activity of progenitor cells in patients with documented diabetes mellitus.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
SDF-1 is an Important Cytokine for Neovascularization. Cleavage of SDF-1 is Reduced by DPPIV Inhibitors
Keywords
CAD, diabetes, SDF-1, endothelial function
7. Study Design
Primary Purpose
Basic Science
Study Phase
Phase 2, Phase 3
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Vildagliptin
Arm Type
Active Comparator
Arm Description
starting with vildagliptin for 30 days followed by placebo for 30 days
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
starting with placebo for 30 days followed by vildagliptin for 30 days
Intervention Type
Drug
Intervention Name(s)
Vildagliptin
Other Intervention Name(s)
Galvus (R)
Intervention Description
Vildagliptin, 50 mg twice a days, orally for 30 days followed by placebo
Primary Outcome Measure Information:
Title
Endothelial Function
Time Frame
30 days
Secondary Outcome Measure Information:
Title
Number and Function of Progenitor Cells
Time Frame
30 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients with diabetes mellitus type 2 under stable medication
HbA1c between 7% an 10%
age between 18 and 80 years
signed informed consent
Exclusion Criteria:
Atrial fibrillation (plethysmographic recordings can only obtained in sinus-rhythm)
CAD with reduced left ventricular ejection fraction (LVEF <45%)
Pregnancy, chronic or acute infection, fever
Diabetes mellitus type 1
Newly diagnosed diabetes, uncontrolled diabetes
Neoplasm
Known allergy to study drug
Severe liver/kidney disease
HIV, Hepatitis
Participation at other studies within the last 30 days
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andreas M. Zeiher, MD
Organizational Affiliation
Cardiology, University of Frankfurt
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Cardiology
City
Frankfurt
ZIP/Postal Code
60590
Country
Germany
12. IPD Sharing Statement
Learn more about this trial
Functional Improvement of Progenitor Cells and Endothelial Function by Vildagliptin in Diabetes Mellitus (FINNjA-DM).
We'll reach out to this number within 24 hrs